8-K: TransCode Therapeutics Announces Rescheduled 2025 Annual Stockholder Meeting and Key Deadlines

TransCode Therapeutics, Inc. has announced a change in the date for its 2025 annual meeting of stockholders to August 29, 2025, and has set new deadlines for stockholder proposals and director nominations.

Summary

• TransCode Therapeutics, Inc. (the "Company") will hold its 2025 annual meeting of stockholders (the "2025 Annual Meeting") on August 29, 2025.
• The record date for stockholders entitled to notice and vote at the 2025 Annual Meeting is the close of business on July 11, 2025.
• The 2025 Annual Meeting date has been changed by more than 30 days from the one-year anniversary of the 2024 Annual Meeting, which was held on June 13, 2024.
• Stockholder proposals intended for inclusion in the proxy statement for the 2025 Annual Meeting under Rule 14a-8 must be submitted in writing by the close of business on June 23, 2025.
• Stockholders wishing to make nominations or introduce business at the 2025 Annual Meeting (outside of Rule 14a-8) must deliver proper notice by the close of business on June 23, 2025.
• Stockholders intending to solicit proxies for director nominees other than the Company's nominees under universal proxy rules (Rule 14a-19) must provide written notice by the close of business on June 23, 2025.

Sentiment

Score: 5

Explanation: The document is neutral in sentiment as it provides purely administrative information regarding the scheduling of the annual meeting and associated deadlines, with no operational or financial updates.

Future Outlook

The document does not provide any forward-looking statements or guidance related to the company's financial performance or operational outlook, focusing solely on administrative matters concerning the upcoming annual meeting.

Management Comments

• The Company intends to hold its 2025 annual meeting of stockholders on August 29, 2025.
• The Company has set the close of business on July 11, 2025, as the record date for the determination of stockholders who are entitled to notice of, and to vote at, the 2025 Annual Meeting.
• As the date of the 2025 Annual Meeting will have been changed by more than 30 days from the one-year anniversary of the 2024 Annual Meeting, the Company is informing stockholders of this change in accordance with Rule 14a-5(f) under the Exchange Act.
• The Company believes June 23, 2025, to be a reasonable deadline under the applicable rules of the Exchange Act for stockholder proposals to be considered for inclusion in this year's proxy materials.

Industry Context

This filing is an administrative update common across publicly traded companies, detailing changes to the annual stockholder meeting schedule and associated deadlines. It does not provide specific insights into TransCode Therapeutics' industry position or competitive landscape beyond standard corporate governance practices.

Corporate Governance

Stakeholder Impact

• Shareholders: Directly impacted by the change in the annual meeting date and the new deadlines for submitting proposals and nominations, requiring them to adjust their schedules and submission plans accordingly.

Next Steps

• The Company will specify the time and location of the 2025 Annual Meeting in its definitive proxy statement on Schedule 14A.
• Stockholders must submit proposals and nominations by June 23, 2025, to be considered for the 2025 Annual Meeting.

Key Dates

Keywords

TransCode Therapeutics, RNAZ, SEC filing, 8-K, annual meeting, stockholders, proxy statement, corporate governance, shareholder nominations, record date